The lung condition known as chronic obstructive pulmonary disease (COPD) is characterized by remodeling non reversibly of the airways, including fibrosis, smooth muscle hyperplasia, and airway inflammation. By interacting with numerous inflammatory mediators and intricate signaling pathways, insulin-like growth factor-I (IGF-I) causes airway remodeling. The form of IGFBPs that is most prevalent is IGFBP-3. IGF-1 is bound by the IGF-1 receptor, IGFBP-3, which prevents IGF-1 from suppressing airway inflammation. IGFBP-3 is crucial in this situation for controlling the inflammatory response. By examining the circulation levels of IGF-1 and IGFBP3 in newly diagnosed and untreated COPD patients, we sought to contribute to the innovative COPD diagnosis and therapy approaches.
 

Download Full Text - PDF